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Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious
puberty (CPP) worldwide and have an enviable track record of safety and efficacy. Recent years have
witnessed much growth in the availability of longer-acting and sustained-release forms of GnRHas.
Although all available agents appear promising, limited long-term follow-up and/or comparative data
are available. In this review, important issues pertaining to the treatment of children with CPP are
discussed. In addition to an assessment of the newer extended-release GnRHa formulations, a de-
lineation of factors essential in determining which children should be treated is offered. Outstanding
uncertainties in clinical management are highlighted and areas in need of future research identified.
Literature searches for this review were performed in PubMed and OVID, with a focus on English-
language publications using the terms “central precocious puberty” and “treatment.”
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Central precocious puberty (CPP) refers to early activation of the hypothalamic-pituitary-
gonadal (HPG) axis and occurs in 1 in 5000 to 10,000 children [1]. CPP is far more common
in girls, in whom it is usually idiopathic. Safe and effective treatment of CPP in the form of
long-acting GnRH analogs (GnRHas) has been available for many years [2].
The development of GnRHas was based on the recognition that sustained high concen-
trations of GnRH resulted in a paradoxical downregulation and subsequent suppression of
the HPG axis [3]. In the early 1980s, several different formulations of GnRHas were de-
veloped with different durations of action and routes of administration. Historically, themost
commonly used preparation in the United States for the treatment of CPP was monthly IM
depot leuprolide [4]. However, during the past decade or so, there has been a substantial
increase in the number of extended-release formulations of GnRHas, resulting in a broad
array of therapeutic options for patients and providers. These include 3-monthly (i.e., once
every 3 months) depot IM preparations, 6-monthly (i.e., once every 6 months) depot IM prep-
arations, and a subcutaneous implant that is marketed for annual use [5].
Although these longer-acting formulations are expected to improve compliance, the cost of
GnRHas developed for use in children has remained extremely high. While minimal com-
parative information about the extended-release options is available in the short term, how
they will stack up in contrast to monthly depot leuprolide regarding long-term safety and
efficacy. Despite the excellent track record achieved in the arena of pharmacologic treat-
ment of CPP, several notable queries remain about clinical management of affected chil-
dren. These include criteria for treatment, the role of psychological considerations, whether
brainMRI scanning should bemandatory, how therapy should bemonitored, andwhen it should
be discontinued. This review discusses each of the extended-release GnRHa formulations
Abbreviations: CNS, central nervous system; CPP, central precocious puberty; GnRHa, GnRH analog; HPG, hypothalamic-pituitary-
gonadal.
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currently in the therapeutic armamentarium, describes areas of uncertainly in clinical
management, and highlights unanswered questions and future directions.
1. Extended-Release GnRHa Preparations
A. Three-Monthly Depot GnRHas
Although 3-monthly depot GnRHas have been used in Europe for the treatment of CPP for
many years [6], the first US Food and Drug Administration approval of a 3-monthly form of
depot leuprolide for pediatric use occurred in 2011. While clinical indices of pubertal sup-
pression have been reassuring, the 11.25-mg 3-monthly dose resulted in,100%HPG-axis
suppression in several studies. These have included trials investigating 1- vs 3-monthly depot
leuprolide [7, 8], a 3-year study of two different doses of depot leuprolide [9], and a meta-
analysis of 3-monthly triptorelin for 1 year [10]. In contrast, one small retrospective study
found no differences in adult height between girls treated with monthly vs 3-monthly
triptorelin at the 11.25-mg dose [11]. Longer and larger-scale follow-up studies are needed to
determine if there are meaningful discrepancies in clinical outcomes resulting from different
doses of 3-monthly GnRHas as compared with monthly treatment.
B. Six-Monthly Depot GnRHas
A 6-monthly form of depot triptorelin was approved in 2017 by the US Food and Drug
Administration for use in CPP. This approval was based on findings from an international,
multicenter study conducted in 44 patients [12]. Appropriate HPG-axis suppression was
noted in 93% of the subjects at 6 months and in 97.7% at 12 months. As with 3-monthly
preparations, parameters indicating efficacy in terms of pubertal progression were favorable.
However, given the limited amount of information available, no firm conclusions can bemade
yet about 6-monthly depot GnRHas. Trials investigating additional 6-monthly preparations
besides triptorelin are underway.
C. Subcutaneous Histrelin Implant
A subcutaneous implant containing 50 mg of the potent GnRHa histrelin has been available
for the treatment of CPP since 2007. Constructed of a soft hydrogel, the device releases
histrelin at a rate of;65 mg/d and results in profound HPG-axis suppression within 1 month
[13]. The implant is typically inserted in the upper inner arm using local anesthesia in most
cases [14]. After 5 years of treatment, predicted adult heights in children naı¨ve to treatment
increased by 9 to 10 cm [15]. Although marketed for annual use, the recognition that a single
implant lasts at least 2 years has the potential to decrease costs and numbers of surgical
procedures in children treated with this modality [16]. Routes of administration, available
doses, and duration of action of each of the extended-release GnRHa preparations available
for use in the United States are summarized in Table 1.
Table 1. Extended-Release Preparations of GnRH Analogs Available in the United States
Generic Name Brand Name (Manufacturer)
Route of
Administration
Available
Doses (mg)
Duration
of Action
3-Monthly leuprolide Lupron Depot-PED 3 mo
(AbbVie, Chicago, IL)
IM 11.25, 30 3 mo
6-Monthly triptorelin Triptodur (Arbor Pharmaceuticals,
Atlanta, GA)
IM 22.5 6 mo
Histrelin implant Supprelin LA (Endo Pharmaceuticals,
Malvern, PA)
Subcutaneous
implant
50 $2 y
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2. Safety of GnRHas
GnRHas have an admirable safety profile. The most commonly reported adverse events are
injection-site reactions which are typically mild and self-limited. However, sterile abscess
formation has been reported in the setting of IM injections [17] and the histrelin implant [18].
The most problematic issue encountered with the histrelin implant is a propensity for the
device to fracture during explanation, which in rare cases has necessitated ultrasound
guidance to remove remaining fragments [19]. During treatment, growth velocity can
significantly decline, particularly in patients with a markedly advanced bone age. This may
necessitate addition of adjunctive treatment in the form of GH or oxandrolone [20]. Although
some children may experience weight gain while on therapy, the preponderance of evidence
suggests that GnRHas do not have a negative effect on body mass index in patients being
treated for CPP [21, 22]. Bone mineral density is typically increased for age at diagnosis and
progressively decreases during GnRHa treatment. However, follow-up of patients several
years after cessation of therapy reveals bone mineral accrual to be within the normal range
compared with population norms [23].
3. Criteria for Treatment
The main goal of treatment in children with CPP is the preservation of height potential.
Although this sounds straightforward, any consideration of height outcomes must ac-
knowledge several limitations. One is that no randomized controlled studies examining the
effect of treatment vs no treatment on height in CPP have ever been conducted, to this
author’s knowledge. Another is that outcome in terms of height is generally based on the
difference between predicted adult height at diagnosis and ultimate adult height at the end of
treatment [24–28]. By definition, height predictions are based on bone-age radiographs,
which are highly imprecise and subject to substantial variability in interpretation. In ad-
dition, bone ages typically over-predict height in CPP [29]. Thus, it is very difficult to ac-
curately predict height outcome for any individual child. In addition to the caveats already
mentioned, the degree of height gained also depends on multiple factors, including chro-
nological age, pubertal stage, skeletal maturation, and tempo of pubertal development. It has
long been recognized that a subset of children with CPP have a slowly progressive form of
early puberty that does not benefit from intervention in terms of adult height [30]. The
challenge lies in identifying which patients will ultimately belong in this category as com-
pared with those who will lose a substantial degree of height potential without treatment.
Therefore, a period of observation of ;6 months has been recommended unless puberty is
quite advanced (Tanner stage $3 breast development in girls) at initial presentation [31].
Paradoxically, the suggestion to wait for some time before initiating therapy is in direct
contradiction to the observation that the benefit gained in terms of height is inversely
proportional to the age at which treatment is started. Girls in whom GnRHa therapy is
initiated at age#6 years derive the greatest benefit from intervention, whereas those who are
treated at between 6 and 8 years have a variable outcome [32, 33]. In contrast, no increase in
adult height is seen in girls who are treated after age 8 years [34, 35]. Despite broad ac-
knowledgment of a lack of increase in adult stature in girls treated when they are older than 8
years, GnRHa treatment continues to be initiated in many children who are well above this
age threshold [36]. This likely reflects parental anxiety regarding impending menses as well
as effective marketing by the producers of GnRHas. Insufficient data regarding boys with
CPP have hampered the establishment of analogous age cutoffs for treatment efficacy in boys.
The other concern often used as a rationale for treatment is negative psychosocial conse-
quences of precocious puberty, particularly in girls. Because of conflicting conclusions in the
medical literature in this area, no clear consensus regarding the risk of psychopathology in
children with CPP exists [37]. Although some studies have indicated increased stress and
anxiety in girls with CPP [38, 39], others have found no differences in psychological func-
tioning as compared with control subjects [40, 41]. This is an area in which more research is
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definitely needed. Table 2 summarizes the results of several studies reporting adult height
outcomes in girls treated for CPP.
4. Controversies in Management of CPP
A. Need for Brain MRI
Once a diagnosis of CPP has been made, clinicians are faced with the decision of whether to
order a brain MRI. This decision only pertains to girls, because the much higher rate of
intracranial pathologymandates central nervous system (CNS) imaging in all boys with CPP.
It has been suggested that brain MRI scanning may not be necessary in girls older than age
6 years who have no neurologic symptoms [42]. However, others have advocated for routine
brain MRIs regardless of age, because of the finding of CNS abnormalities in girls with CPP
who are older than age 6 years [43]. Potential consequences of unnecessaryMRIs include cost,
parental anxiety, and need for repeated imaging when incidental findings are uncovered. A
meta-analysis of MRI findings in children with CPP revealed a total prevalence of CNS
lesions of 9%, which decreased to 7%when only those possibility related to early puberty were
included [44]. Notably, however, only 1.6% of these required intervention, because the vast
majority were hypothalamic hamartomas which respond to medical therapy. Given that a
small risk of important CNS abnormalities does exist, it is unlikely that the controversy
surrounding this aspect of management will be resolved any time soon. For now, the rec-
ommendation is to discuss the pros and cons of MRI scanning with parents and allow them to
participate in the decision of whether or not to pursue this test [45].
In children with a family history of CPP, genetic testing for anMKRN3mutation, the most
common monogenetic cause of precocious puberty, will likely supersede CNS imaging,
rendering this issue moot in many cases [46]. A second genetic etiology underlying familial
CPP is deletions in DLK1, which encodes for Delta-Like 1 Homolog [47]. Both MKRN3 and
DLK1 are maternally imprinted genes that are expressed only from the paternal allele.
Thus, a family history of CPP on the father’s side should increase the index of suspicion for a
Table 2. Examples of Studies Reporting Adult Height in Girls Treated With a GnRHa for CPP
First Author
Year of
Publication
No. of Girls
Participating
Modality Used and
Duration of GnRH
Treatmenta
Adult Height
Achieved,
Mean 6 SD (cm)
Height Increase
Above Predicted
at Baseline (cm)
Heger [24] 1999 50 Depot triptorelin
4.4 6 2.1 y
160.6 6 8.0 5.7
Antoniazzi [25] 2000 71 Depot triptorelin,
buserelin nasal
spray 16–56 mo
154.4 6 5.6 2-7
Lazar [32] 2007 115 Depot decapeptyl
2.8–4.8 y
160.35 6 5.05 5
Pasquino [26] 2008 87 Depot triptorelin
4.2 6 1.6 y
159.8 6 5.3 5.1
Nabhan [27] 2009 26 Depot leuprolide
3.6 6 2.1 y
163 6 7.6 4.5
Magiakou [22] 2010 33 Depot triptorelin
2.75 y
158.5 6.95
Poomthavorn [21] 2011 47 Depot leuprolide or
triptorelin
3.4 6 1.5 y
158.6 6 5.2 4.7
Bertelloni [11] 2015 25 Depot triptorelin,
3.05 6 0.9 y
158.25 6 5.8 3
Lee [28] 2018 84 Depot leuprolide
2.98 6 0.73 y
160.1 6 5 4
aDuration data reported as mean 6 SD or as a range.
968 | Journal of the Endocrine Society | doi: 10.1210/js.2019-00036
mutation in one of these genes. Other genetic causes of CPP include activating mutations in
kisspeptin and its receptor, KISS1R [48, 49]. However, each of these has been described as
causing CPP in only a single patient thus far [50].
B. Monitoring of Treatment
There is no systematic strategy formonitoringwhether adequate suppression of theHPGaxis
has been achieved in children being treated for CPP [51]. Although there is unanimity re-
garding the value of auxologic indices such as growth velocity, Tanner staging, and skeletal
maturation, no agreement exists on the need for biochemical measures of treatment efficacy
[52]. In fact, unexpected pitfalls are sometimes encountered when assumptions are made
about hormonal studies in CPP. A case in point is the use of random ultrasensitive LH
concentrations, which are helpful in the diagnosis of CPP and were postulated to adequately
reflect HPG-axis suppression during treatment. Unexpectedly, random ultrasensitive LH
values frequently remain in the pubertal range in children receiving GnRHa therapy that
otherwise provides adequate HPG-axis suppression, and therefore these values can be
misleading [53, 54]. Given the lack of evidence for any association between biochemical
monitoring and adult height, it is reasonable to forgo any routine blood testing in children
being treated for CPP. If treatment failure is suspected on clinical grounds, a GnRHa
stimulation test is recommended.
C. Discontinuation of Therapy
A final area of uncertainty in the management of CPP relates to the optimal age of dis-
continuation of treatment. There are essentially no studies in which age at treatment ces-
sation has been standardized. However, cumulative evidence suggests that optimal height
gains are realizedwhen treatment is stopped at a bone age of;12 years in girls and;13 years
in boys [37, 55, 56]. Regardless, the decision of when to halt therapy is individualized and
incorporates numerous patient-specific characteristics including absolute and predicted
height, chronological age, psychosocial factors, pubertal stage, and family preferences.
D. Gonadal Function After GnRHa Therapy
Information regarding long-term outcomes of patients treated with GnRHas with respect to
gonadal function are reassuring. Unsurprisingly, the vast majority of existing data pertain
only to women. Menstrual cycles are reported to be normal with respect to duration and
timing, and mean ovarian volumes similar to those in the general population. There have
been no perceived health consequences to offspring of mothers who were treated with
GnRHas and no increased need for assisted reproductive technology [57, 58]. Limited follow-
up in adolescent boys previously treated with a GnRHa for CPP reveals similarly normal
testicular function and sperm counts within the normal range [59], although more data in
men are needed.
5. Conclusion
The therapeutic armamentarium for the treatment of children with CPP has rapidly ex-
panded, resulting in the availability of several newer extended-release GnRHa formulations.
Although the efficacy and safety of these longer-acting agents are not expected to diverge
from historically used preparations, only amodicum of information regarding some of them is
available. Likewise, a lack of head-to-head comparison data renders it impossible to de-
termine whether any relative superiority among these different treatment options exists.
Despite the highly favorable treatment profile of CPP in general, there are several unresolved
questions pertaining to clinical management of affected children. Areas particularly in need
of additional research include psychological sequelae of CPP and height outcomes in boys.
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Efforts aimed at determining the optimal strategy for monitoring treatment and time for
discontinuation of GnRHa therapy are also needed.
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